June 19, 2018 07:51 AM EDT
Financing

Mega-mon­ey biotech round spills $116M in­to gene ther­a­py up­start Free­line

John Carroll

Editor & Founder

The mega-mon­ey pour­ing in­to biotechs isn’t re­strict­ed to the US. Uni­ver­si­ty Col­lege Lon­don spin­out Free­line just scored a $116 mil­lion Se­ries B, with heavy­weight health­care …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times